RESUMO
PURPOSE: To investigate the treatment outcomes of extracranial oligometastatic colorectal cancer (CRC) patients treated with stereotactic body radiotherapy (SBRT). MATERIALS AND METHODS: The clinical data of 388 extra-cranial oligometastatic CRC (≤â¯5 lesions) patients and 463 lesions treated with SBRT at 19 cancer institutions were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local control (LC) were assessed in uni- and multivariable analyses. RESULTS: The median age was 62 years (range, 29-92 years). The majority of the patients (90.5%) received surgery and systemic treatment for their primary tumor, had ≤â¯2 metastasis (83.3%), had single organ involvement (90.3%), and staged using flouro-deoxyglucose positron emission tomography (FDG-PET/CT) (76%). The median fraction and total radiation doses were 10â¯Gy (range: 6-34â¯Gy) and 50â¯Gy (range: 8-64â¯Gy), respectively, delivered in a median of 4 fractions (range: 1-8). The median follow-up time for the entire cohort was 30.7 months (interquartile range: 27.0-34.3 months). The 3year OS, PFS, and LC rates were 64.0%, 42.3%, and 72.7%, respectively. The 3year LC rate was significantly higher in patients receiving BED10â¯≥â¯100â¯Gy than those receiving BED10â¯<â¯100â¯Gy (76.0% vs. 67.3%; pâ¯= 0.04). The 3year PFS and OS rates were higher in patients receiving BED10â¯≥â¯100â¯Gy than those receiving BED10â¯<â¯100â¯Gy (33.2% vs. 25.2%; pâ¯= 0.03; 53.7% vs. 44.8%; pâ¯= 0.02). Single metastasis and complete response after SBRT were independent prognostic factors for survival in multivariable analysis. CONCLUSIONS: In this multi-center study, we demonstrated that SBRT is an effective treatment option of metastatic lesions in oligometastatic CRC patients by providing promising LC rates. Higher SBRT doses beyond BED10â¯≥â¯100â¯Gy were associated with improved LC and survival. LC of treated lesion and lower tumor burden after SBRT were associated with better outcomes.
RESUMO
OBJECTIVE: To investigate interfractional motion of the mesorectum and bladder and to assess dosimetric changes using cone-beam computed tomography (CBCT) during neoadjuvant radiotherapy for locally advanced rectal cancer patients. METHODS: Twenty-one patients who underwent volumetric arc therapy with CBCT imaging protocol were retrieved. The mesorectum and bladder were delineated on every CBCT image, and treatment plans were recalculated for all CBCTs. The organ motion was analyzed as a mean shift on the X-Y-Z axes. The volume changes were evaluated using the DICE index. Mann-Whitney U test was used in pairwise comparison analysis and ANOVA was used to compare shifts in each direction. RESULTS: A total of 105 CBCTs were evaluated retrospectively. The movement of the total mesorectum was found to be 1.5 mm, 4 mm, and 5 mm on the X-Y-Z-axes, respectively. In the subgroup analysis, the movement of the 1/3 upper mesorectum on the Y-axis was significantly higher (mean movement 8 mm, p = 0.005). Mean bladder displacements were 2 mm, 4 mm, and 8 mm on the X-Y-Z-axes, respectively. In the D2, D95, and D98 doses, there was no statistically significant change depending on the motion. CONCLUSION: During radiotherapy planning, the mesorectal movement should not be forgotten and PTV margins should be determined accordingly (Tab. 6, Ref. 22). Text in PDF www.elis.sk Keywords: cone-beam computed tomography, rectal cancer, mesorectum, interfractional organ motion, neoadjuvant radiotherapy.
Assuntos
Movimentos dos Órgãos , Neoplasias Retais , Humanos , Terapia Neoadjuvante , Estudos Retrospectivos , Planejamento da Radioterapia Assistida por Computador/métodos , Neoplasias Retais/diagnóstico por imagem , Neoplasias Retais/radioterapia , Tomografia Computadorizada de Feixe Cônico/métodos , Dosagem RadioterapêuticaRESUMO
Background: The aim of this study was to investigate the recurrence patterns in pancreatic cancer patients treated with adjuvant intensity modulated radiotherapy (IMRT) and to correlate the sites of locoregional recurrence with radiotherapy target volumes. Materials and methods: Thirty-eight patients who had undergone resection and adjuvant chemoradiation for pancreatic cancer were evaluated. Radiotherapy (RT) was started after 1-3 cycles of adjuvant chemotherapy (CHT). Clinical target volume (CTV) was contoured according to the RTOG guideline. All patients were treated with IMRT with a dose of 45-50.4 Gy. Computerized tomography (CT) images at the time of recurrence were correlated with radiotherapy plans. Locoregional recurrences were classified as in-field, out-field and marginal. Results: Median overall survival (OS) was 19 months. One- and 2-year OS rates were 73.6% and 37.1%, respectively. Locoregional recurrence and distant metastases were observed in 11 (28.9%) and 23 (60.5%) patients, respectively. For the 11 locoregional recurrences, 7 were in-field, 1 was marginal, and 3 were out-of-field. One patient had isolated local, 2 patients had isolated regional and 15 (57.6%) patients had only distant failures. The first presentations of failures were mostly distant (58%). On multivariate analysis, tumor size ≥ 3 cm (p = 0.011) and positive vascular invasion (p = 0.014) predicted for worse OS rate. Conclusions: The majority of locoregional recurrences were in the radiation field among pancreatic cancer patients treated with postoperative IMRT. However, failures were predominantly distant, and improvement of systemic control may be of particular interest.
RESUMO
OBJECTIVE: Today, respiratory movement can be monitored and recorded with different methods during a simulation on a four-dimensional (4D) computed tomography (CT) device to be used in radiotherapy planning. A synchronized respiratory monitoring system (RPM) with an externally equipped device is one of these methods. Another method is to create 4D images of the patient's breathing phases without the need for extra equipment, with an anatomy-based software program integrated into the CT device. Our aim is to compare the RPM system and the software system (Deviceless) which are two different respiratory monitoring methods used in tracking moving targets during 4D-CT imaging and to assess their clinical usability. METHODS: Ten patients who underwent paraaortic nodal irradiation were enrolled. The simulation was performed using intravenous contrast material on a 4D-CT device with both respiratory monitoring methods. The right/left kidneys and renal arteries were chosen as references to evaluate abdominal organ movement. It was then manually contoured one by one on both sets of images. The images were compared volumetrically and geometrically after rigid reconstruction. The similarity between the contours was determined by the Dice index. Wilcoxon test was used for statistical comparisons. RESULTS: The motion of the kidneys in all three directions was found to be 0.0 cm in both methods. The shifts in the right/left renal arteries were submillimetric. The Dice index showed a high similarity in both kidney and renal artery contours. CONCLUSION: In our study, no difference was found between RPM and Deviceless systems used for tracking and detection of moving targets during simulation in 4D-CT. Both methods can be used safely for radiotherapy planning according to the available possibilities in the clinic.
RESUMO
With the advances in radiation technology, skin reaction due to postoperative radiotherapy (RT) in breast cancer patients is generally mild and tolerable. However, certain drugs may increase the radiation effect. In literature, only few cases of adverse reactions in the radiation field have been reported with the use of Chloroquine. This report describes the case of a 30-year-old young female who had enhanced skin reactions with hydroxychloroquine (HCQ) treatment during breast RT. HCQ should be used with caution in patients undergoing RT due to its potential radiosensitizer effect.
Assuntos
Neoplasias da Mama , Hidroxicloroquina , Humanos , Feminino , Adulto , Hidroxicloroquina/efeitos adversos , Cloroquina/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/radioterapiaRESUMO
OBJECTIVE: The association of treatment-related side effects and tumor characteristics with sexual function, depression, and anxiety were investigated in patients with locally advanced rectum cancer (LARC) receiving neoadjuvant chemoradiotherapy (CRT). MATERIAL AND METHODS: Thirty-two patients who received neoadjuvant CRT with LARC were included. The Arizona Sexual Experiences (ASEX) Scale was used to determine the sexual function status whereas the Beck Depression Inventory (BDI) and the Beck Anxiety Inventory (BAI) were used to evaluate the depression and anxiety status of the patient, respectively. The patients were asked to fill these scales before and at least 4 weeks after the neoadjuvant CRT. T-test and Mann-Whitney U test were used for the comparison of values. RESULTS: Median age was 52.5 years (range: 33-76). Twenty-six patients were male, and 6 patients were female. At presentation, the tumor was located mostly in lower third rectum (72%), and 69% of the patients had T3 tumors. There was a statistically significant deterioration in the sexual functions of the patients (p < 0.001), a statistically significant decrease in their anxiety level after CRT (p: 0.037). Depression level was changed from mild to minimal during this process (p: 0.17). A significant deterioration in the ASEX scale was observed especially in patients with grade 2 and above gastrointestinal side effects (p: 0.01). CONCLUSION: This prospective study showed that the patient's anxiety and depression levels had decreased during the treatment process probably due to the decrease in the patient's symptoms. However, deterioration of the sexual function status which might be correlated to increased gastrointestinal side effects during CRT has been observed. So, clinical and psychiatric support including therapies for sexual dysfunctions is needed for LARC patients during and after the neoadjuvant CRT.
Assuntos
Terapia Neoadjuvante , Neoplasias Retais , Humanos , Masculino , Feminino , Pessoa de Meia-Idade , Terapia Neoadjuvante/efeitos adversos , Depressão/diagnóstico , Depressão/etiologia , Estudos Prospectivos , Neoplasias Retais/terapia , Neoplasias Retais/patologia , Ansiedade/diagnóstico , Ansiedade/etiologia , Quimiorradioterapia/efeitos adversos , Resultado do TratamentoRESUMO
BACKGROUND AND AIM: This study aimed to determine treatment outcomes and factors affecting prognosis in patients diagnosed with anal canal cancer who received radical radiotherapy (RT) or radiotherapy combined with chemotherapy (CT-RT) in radiation oncology centers in Turkey and compare the results with literature. MATERIAL AND METHOD: The study included 193 patients with anal canal cancer reported between 1995 and 2019, of which 162 had complete data. The study was conducted in 11 radiation oncology centers, and a joint database was shared among them. Patients received radiotherapy doses of 45 Gy to 60 Gy. Data analysis was done using SPSS for Windows version 20. RESULTS: Median follow-up was 48.51 months (2-214). All patients received radiotherapy, and 140 (86.4%) received concurrent chemotherapy. Radiotherapy doses of 50.4 Gy to 60 Gy were administered to 74 patients (45.7%) using 2-dimensional-3-dimensional (2D-3D) conformal therapy and 70 patients (43.2%) using intensity modulated radiotherapy technique (IMRT). Acute phase hematologic toxicity was observed in 62 patients (38.3%), and nonhematologic toxicity in 123 patients (75.9%). The 5-year overall survival (OS) rate was 75.1% and disease-specific survival (DSS) rate was 76.4%. OS without colostomy was achieved in 79,8 % at 5 years, and complete response in 112 patients (69.1%). OS rate was significantly higher in 142 patients with positive response (P < .000) and 112 with complete response (P < .000). Anemia (P < .002), local progression, and systemic progression (P < .000) resulted in lower OS (P < .002). In univariate analysis, factors affecting OS rate were: gender, age, stage, lymph node status, T stage, RT treatment duration, and treatment planning with PET fusion, which were found to be statistically significant. Completing radiotherapy in less than 45 days, concurrent chemotherapy, and continued administration of mitomycin and 5 FU as chemotherapy had a significant positive effect on overall survival. OS rate was higher in patients receiving RT dose of 58 Gy or less and undergoing IMRT planning in radiotherapy. IMRT was associated with lower acute and late side effects. CONCLUSION: Radiochemotherapy is the primary treatment for anal canal cancer and advanced radiotherapy techniques may increase survival by reducing side effects and improving treatment continuation. Higher treatment doses require further investigation. The efficacy of treatment can be improved by including patients treated with modern radiotherapy techniques in multicenter prospective studies using new and more effective chemotherapy and immunotherapy agents.
Assuntos
Neoplasias do Ânus , Neoplasias , Radioterapia (Especialidade) , Radioterapia de Intensidade Modulada , Humanos , Canal Anal/patologia , Estudos Prospectivos , Intervalo Livre de Doença , Fluoruracila , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Quimiorradioterapia/efeitos adversos , Quimiorradioterapia/métodos , Radioterapia de Intensidade Modulada/efeitos adversos , Radioterapia de Intensidade Modulada/métodos , Mitomicina/uso terapêutico , Neoplasias/tratamento farmacológico , Neoplasias do Ânus/patologiaRESUMO
BACKGROUND: Encapsulated papillary carcinoma (EPC) is a rare malignant papillary breast cancer accounting for approximately .5%-2% of all breast tumors. The aim of this multicenter study was to evaluate clinicopathologic features of EPC in addition to oncological outcomes and radiotherapy (RT) details. METHODS: From 10 different academic hospitals in Turkey, we obtained pathology reports of 80 patients with histologically confirmed EPC between 2005 and 2022. Demographic, diagnostic, and treatment data were collected from medical records, retrospectively. Local failure, distant progression, toxicity-adverse effects, overall survival (OS), and disease-free survival were evaluated, and survival analyzes were performed using the Kaplan-Meier method. RESULTS: Eighty patients with the diagnosis of misspelled sorry (ECP) were retrospectively evaluated. The median age of the patients was 63 (range, 35-85). After a median follow-up of 48 (range; 6-206) months, local recurrence was observed in three patients (4%). Local recurrence was less common in the patients who received whole breast RT with a tumour bed boost (p = .025). There were not any distant metastasis or disease-related death. RT was applied to 61% of the cases, and no treatment-related grade 3 or higher toxicity was reported in any of the patients. Five year OS, cancer-specific survival (CSS), and were observed as 85%, 100%, and 96%, respectively. CONCLUSIONS: ECP is a rare, slow-progressing breast carcinoma associated with good prognosis, it is a disease of elderly patient, and usually occurs in postmenopausal women. It responds extremely well to optimal local treatments and appropriate adjuvant treatments on a patient basis, and has excellent OS and CSS ratios.
Assuntos
Neoplasias da Mama , Carcinoma Papilar , Radioterapia (Especialidade) , Idoso , Feminino , Humanos , Neoplasias da Mama/patologia , Carcinoma Papilar/radioterapia , Carcinoma Papilar/patologia , Recidiva Local de Neoplasia/patologia , Estudos Retrospectivos , Turquia/epidemiologia , Adulto , Pessoa de Meia-Idade , Idoso de 80 Anos ou maisRESUMO
The aim of this study was to examine the prognostic factors and treatment outcomes of cervical esophageal carcinoma (CEC) patients who underwent definitive chemoradiotherapy (CRT). The clinical data of 175 biopsy-confirmed CEC patients treated with definitive CRT between April 2005 and September 2021 were retrospectively analyzed. The prognostic factors predicting overall survival (OS), progression-free survival (PFS), and local recurrence-free survival (LRFS) were assessed in uni- and multivariable analyses. The median age of the entire cohort was 56 years (range: 26-87 years). All patients received definitive radiotherapy with a median total dose of 60 Gy, and 52% of the patients received cisplatin-based concurrent chemotherapy. The 2-year OS, PFS, and LRFS rates were 58.8%, 46.9%, and 52.4%, respectively, with a median follow-up duration of 41.6 months. Patients' performance status, clinical nodal stage, tumor size, and treatment response were significant prognostic factors for OS, PFS, and LRFS in univariate analysis. Non-complete treatment response was an independent predictor for poor OS (HR = 4.41, 95% CI, 2.78-7.00, p < 0.001) and PFS (HR = 4.28, 95% CI, 2.79-6.58, p < 0.001), whereas poor performance score was a predictor for worse LRFS (HR = 1.83, 95% CI, 1.12-2.98, p = 0.02) in multivariable analysis. Fifty-two patients (29.7%) experienced grade II or higher toxicity. In this multicenter study, we demonstrated that definitive CRT is a safe and effective treatment for patients with CEC. Higher radiation doses were found to have no effect on treatment outcomes, but a better response to treatment and a better patient performance status did.
Assuntos
Carcinoma , Neoplasias Esofágicas , Neoplasias do Colo do Útero , Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Estudos Retrospectivos , Neoplasias Esofágicas/terapia , QuimiorradioterapiaRESUMO
PURPOSE: To investigate the predictive and prognostic role of pretreatment hematological parameters for tumor response and outcomes in locally advanced rectal cancer (LARC) patients undergoing surgery after neoadjuvant chemoradiotherapy (nCRT). METHODS: From 2010 to 2016, 53 patients with LARC who underwent surgery following nCRT were analyzed. All hematological parameters were obtained from the initial blood tests performed before nCRT. The optimal cutoff values of significant hematological parameters for pathological tumor response (pTR), disease-free survival (DFS), and overall survival (OS) were determined using receiver operating characteristic (ROC) analysis. Patients have categorized into "good" and "poor" response groups according to their pathological results, and clinical-pathologic variables compared between the two groups. All survival analysis was calculated by the Kaplan-Meier method. Uni-multivariate analyses were performed using the Cox proportional hazard model. RESULTS: In the ROC analysis, neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) for OS and absolute platelet count and PLR for DFS were found as significant prognostic factors. In multivariate analysis, surgical margin, ypN stage, and elevated PLR were significantly associated with OS, and likewise, high PLR was found as an independent poor prognostic factor for DFS. The 5-year OS and DFS rates were worse in patients with high PLR group (82.3 vs. 47.3% for OS, p = 0.018 and 88.2 vs. 51.3% for DFS, p = 0.002). CONCLUSION: Pretreatment high PLR is associated with worse OS and DFS in patients with rectal cancer. To use in daily practice, further studies are needed on its validation.
Assuntos
Terapia Neoadjuvante , Neoplasias Retais , Humanos , Linfócitos/patologia , Neutrófilos/patologia , PrognósticoRESUMO
Due to the prolongation of a lifetime, more cancer patients with cardiac implantable electronic devices are treated by radiotherapy. However, radiation may cause permanent or temporary malfunctions on these devices, and new-generation devices are more sensitive to radiation. Besides, radiotherapy techniques and image guidance methods that may cause different interactions with the functions of the devices have been changed significantly recently. Here, we reported our clinical experience in a patient with a pacemaker who underwent radiotherapy with intensity-modulated radiation therapy (IMRT) due to gastric cancer and reviewed the literature.
Assuntos
Bloqueio Atrioventricular/terapia , Carcinoma/terapia , Marca-Passo Artificial/efeitos adversos , Radioterapia de Intensidade Modulada/métodos , Neoplasias Gástricas/terapia , Bloqueio Atrioventricular/complicações , Carcinoma/complicações , Carcinoma/diagnóstico , Carcinoma/patologia , Fracionamento da Dose de Radiação , Evolução Fatal , Gastrectomia , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Planejamento da Radioterapia Assistida por Computador/métodos , Radioterapia Adjuvante/métodos , Neoplasias Gástricas/complicações , Neoplasias Gástricas/diagnóstico , Neoplasias Gástricas/patologiaRESUMO
To determine clinically the fetal dose from irradiation of Hodgkin's disease during pregnancy and to quantify the components of fetal dose using phantom measurements. The fetal dose was measured with phantom measurements using thermoluminescent dosemeters (TLDs). Phantom measurements were performed by simulating the treatment conditions on an anthropomorphic phantom. TLDs were placed on the phantom 41, 44, 46.5 and 49.5 cm from the centre of the treatment field. Two TLDs were placed on the surface of the phantom. The estimated total dose to all the TLDs ranged from 8.8 to 13.2 cGy for treatment with (60)Co and from 8.2 to 11.8 cGy for 4 MV photons. It was concluded that the doses in different sections were evaluated to investigate dose changes in different points and depths of fetal tissues in phantom. Precise planning and the use of supplemental fetal shielding may help reduce fetal exposure.
Assuntos
Carga Corporal (Radioterapia) , Exposição Ambiental/análise , Exposição Materna , Modelos Biológicos , Efeitos Tardios da Exposição Pré-Natal , Radiometria/métodos , Simulação por Computador , Feminino , Humanos , Gravidez , Prótons , Doses de Radiação , Radiometria/normasRESUMO
OBJECTIVE: To assess the prognostic factors and results of limb sparing surgery and postoperative radiotherapy (PORT) in patients with non-metastatic soft tissue sarcomas (STS) of the extremities. METHODS: Between 1980-2007, 114 extremity-located STS treated with PORT were analyzed retrospectively. Tumors were mostly localized in the lower extremities (71,9%). The median radiotherapy (RT) dose was 60.9 Gy. Chemotherapy was administered to 37.7% of the patients. Tumor sizes were between 3-26 cm (median 7 cm). The three most frequent histological types included undifferentiated pleomorphic sarcoma (26.3%), liposarcoma (25.4%), and synovial sarcoma (13.2%). The median follow-up for all patients was 60 months, and 81 months for survivors. RESULTS: The 5- and 10-year local control (LC) rates were 77% and 70.4%, respectively; actuarial survival rates for 5 and 10 years were 71.8% and 69.1%, respectively. Increasing the dose above 60 Gy for all patients and the patients with positive margins demonstrated a clear benefit on 5-year LC (p=0.03 and p=0.04, respectively). Based on multivariate analysis, the addition of chemotherapy and RT dose were independent prognostic factors for LC. A recurrent presentation significantly affects the disease-free survival. CONCLUSIONS: PORT for STS of the extremities provides good long-term disease control with acceptable toxicity in a multidisciplinary approach. Level of evidence III, Retrospective study .
OBJETIVO: Avaliar os fatores prognósticos e os resultados da cirurgia poupadora de membro e radioterapia pós-operatória em pacientes com sarcomas de partes moles das extremidades. MÉTODOS: Entre 1980 e 2007, 114 sarcomas de partes moles localizados em extremidades tratados com cirurgia poupadora de membro e radioterapia pós-operatória foram analisados restrospectivamente. Os tumores localizavam-se principalmente na região mais baixa (71,9%). A dose média da radioterapia foi de 60,9 Gy. A quimioterapia foi usada em 37,7% dos pacientes. Os tamanhos do tumores estiveram entre 3 e 26 cm (mediana de 7 cm). Os três tipos histológicos mais frequentes foram, respectivamente, sarcoma pleomórfico indiferenciado (26,3%), lipossarcoma (25,4%) e sarcoma sinovial (13,2%). O tempo médio de acompanhamento para todos os pacientes foi de 60 meses e 81 meses para sobrevivente. RESULTADOS: As taxas de controle local para 5 e 10 anos foram de 77% e 70,4%, respectivamente, e as taxas de sobrevida foram de 71,8% e 69,1%. Aumentar a dose acima de 60 Gy para todos os pacientes e para aqueles com margens positivas demonstrou claro benefício no controle local de 5 anos (p = 0,03 e p = 0,04, respectivamente). Considerando a análise multivariada, a adição de quimioterapia e a dose de radioterapia foram fatores prognósticos independentes para controle local. Apresentação recorrente afetou significativamente a sobrevida livre da doença. CONCLUSÕES: A cirurgia poupadora de membro e radioterapia pós-operatória para sarcomas de partes moles das extremidades fornece bom controle da doença a longo prazo, com toxicidade aceitável na abordagem multidisciplinar. Nível de evidência III, Estudo retrospectivo.
RESUMO
PURPOSE: Our objective was to analyze kidney damage using glomerular filtration rate (GFR) and dynamic renal scintigraphy (DRS) compared with dose volume histogram (DVH) parameters in gastric cancer patients. MATERIALS AND METHODS: Twenty-two gastric cancer patients treated with postoperative chemoradiotherapy were retrospectively evaluated. Student's t test was used to compare pre- and posttreatment GFR and creatinine values. The relative contribution of the left and right kidney in DRS results was expressed as left-to-right ratio (L/R), and the percentage of initial and control participation ratio difference was calculated. Spearman's correlation analysis was used to compare the percentage difference of L/R ratio with DVH parameters of each kidney. RESULTS: In DRS analysis, decrease in left kidney cortical function was observed in one patient. V5-V10 of the left and bilateral kidneys were significantly associated with GFR decline. None of the DVH parameter was significantly associated with L/R ratio. However, the V15 and Dmean of the bilateral kidney were significantly correlated with greater decrease in L/R ratio in seven patients whose posttreatment DRS period was > 12 months. CONCLUSIONS: Decline in renal function, even with current renal constraints, was observed. Minimization of V5, V10, and V15 and mean dose (Dmean) to the kidney should be considered.
Assuntos
Quimiorradioterapia Adjuvante/métodos , Rim/fisiopatologia , Rim/efeitos da radiação , Neoplasias Gástricas/terapia , Adulto , Idoso , Creatinina , Feminino , Seguimentos , Taxa de Filtração Glomerular/fisiologia , Humanos , Rim/diagnóstico por imagem , Testes de Função Renal/estatística & dados numéricos , Masculino , Pessoa de Meia-Idade , Cintilografia , Dosagem Radioterapêutica , Estudos Retrospectivos , Neoplasias Gástricas/fisiopatologiaRESUMO
BACKGROUND: Desmoid tumors are uncommon and benign mesenchymal neoplasms. The optimal treatment of patients with desmoid tumors is still controversial. Surgery is the primary treatment for locally invasive or recurrent desmoid tumors. Also, radiotherapy is a treatment option for patients at high risk for local failure such as those with positive margins or recurrent and unresectable tumors. AIMS: To report our institutional experience and long-term results of patients with desmoid tumors who received radiotherapy. STUDY DESIGN: Retrospective cross-sectional study. METHODS: Between 1980 and 2009, 20 patients who received radiotherapy (RT) in our institution were analyzed. The majority of patients (80%) were referred with a recurrent tumor after previous surgery. Thirteen patients underwent marginal resection, 4 had wide local excision and 3 patients had only biopsy. Resection margin was positive in 15 (75%) patients. All patients received radiation therapy. The median prescribed dose was 60 Gy. Five patients received less than 54 Gy. RESULTS: The median follow-up time was 77.5 months (28-283 months). Nine patients developed local recurrence after RT. Seven local failures (78%) were in field. Time to local recurrence ranged from 3-165 months (median 33 months). The 2-5 year local control (LC) rates were 80% and 69%, respectively. On univariate analysis, the 5 year local control rate was significantly better in the patients treated with ≥54 Gy than in patients who received <54 Gy (p=0.023). The most common acute side effect was grade 1-2 skin toxicity. As a late side effect of radiotherapy, soft tissue fibrosis was detected in 10 patients and lymphangitis was seen in 1 patient. One patient developed radiation-induced sarcoma. CONCLUSION: According to our results, radiotherapy is especially effective in recurrent disease and provides a high local control rate in the patients received more than 54 Gy.
RESUMO
PURPOSE: To assess the role of preoperative radiotherapy in patients with nonmetastatic high-grade osteosarcoma of the extremities for limb-sparing surgery and to compare the response of neoadjuvant therapies, local control, and survival with the literature results. METHODS AND MATERIALS: Forty-six patients with osteosarcoma of the limbs who were treated within a limb salvage protocol including preoperative radiotherapy and chemotherapy between 1987 and 2002, were retrospectively analyzed. Median age was 17 years (range, 14-66 years). Treatment was started with neoadjuvant chemotherapy. Cisplatin, epidoxorubicin, ifosfamide, and methotrexate were used in different combinations. Preoperative radiotherapy was applied, usually between the second and third cycle of chemotherapy. Radiotherapy was given (35 Gy in 10 fractions) to 44 patients. Two patients were treated with 46 Gy at 2 Gy/day. Definitive surgery was administered after the third course of chemotherapy. Chemotherapy was complete 6 courses postsurgery. RESULTS: Median follow-up time was 44 months (range, 2-154 months). Forty-four patients had limb-sparing surgery, whereas 2 had amputation. Tumor necrosis rate was >/=90% in 87% of the patients (Huvos Grade 3-4). Two patients had local failures, and 26 patients (56.5%) had distant metastases. The 5-year local control and overall survival rates were 97.5% and 48.4%, respectively. On univariate analysis, age =18 years, Huvos Grade 4, lower-extremity localization, and surgery within 1 month significantly survived better than the others. On multivariate analysis, Huvos grade (p = 0.01), age (p = 0.01), interval between neoadjuvant chemotherapy and surgery (p = 0.02), and extremity localization (p = 0.02) were significant prognostic factors for actuarial survival. Severe complication developed in 20% of the patients. CONCLUSION: Preoperative radiotherapy helps to increase the chance of extremity-sparing surgery with good local control and necrosis rate when combined with chemotherapy.
Assuntos
Neoplasias Ósseas , Salvamento de Membro , Osteossarcoma , Adolescente , Adulto , Idoso , Amputação Cirúrgica , Análise de Variância , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Ósseas/radioterapia , Neoplasias Ósseas/cirurgia , Quimioterapia Adjuvante , Cisplatino/administração & dosagem , Epirubicina/administração & dosagem , Extremidades , Humanos , Ifosfamida/administração & dosagem , Masculino , Mesna/administração & dosagem , Metotrexato/administração & dosagem , Pessoa de Meia-Idade , Osteossarcoma/tratamento farmacológico , Osteossarcoma/radioterapia , Osteossarcoma/cirurgia , Prognóstico , Dosagem Radioterapêutica , Estudos Retrospectivos , Taxa de SobrevidaRESUMO
PURPOSE: To analyze the results and evaluate the prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. METHODS AND MATERIALS: Forty-one patients with locally recurrent nasopharyngeal carcinoma, who were reirradiated between 1979 and 2000, were retrospectively analyzed. There were 32 men and 9 women with median age of 46 years. Histologically, 9 tumors (22%) were World Health Organization (WHO) I, 17 (41.5%) WHO II, and 15 (36.5%) WHO III. According to the 1998 TNM staging system of the American Joint Committee on Cancer, the recurrent disease was Stage I in 5 (12.2%), Stage II in 11 (26.8%), Stage III in 6 (14.6%), and Stage IV in 19 (46.4%) patients. Treatment was delivered with 4-6 MV X-rays or Co-60 gamma rays. The median reirradiation dose was 50 Gy. Treatment was delivered at 1.8-2 Gy/fraction daily, 5 days a week. Chemotherapy was used in 41.5% of the patients. RESULTS: Median follow-up was 23 months (range, 3-143 months). The 2-year and 5-year local progression-free and overall survival rates were 39%, 23%, 48%, and 28%, respectively. On univariate analysis, age (p = 0.04), total reirradiation dose (p = 0.0008) were significant prognostic factors for local progression-free rate. For overall survival age, total reirradiation dose, stage, T stage were significant. On multivariate analysis only total dose (p = 0.005) remained significant for local progression-free rate and total reirradiation dose (p = 0.02), interval to recurrence (p = 0.03), stage (p = 0.018) were significant for overall survival. CONCLUSIONS: Early diagnosis of local recurrence and high-dose reirradiation (60 Gy) are crucial for improving the local control and survival.
Assuntos
Carcinoma/radioterapia , Neoplasias Nasofaríngeas/radioterapia , Recidiva Local de Neoplasia/radioterapia , Adolescente , Adulto , Idoso , Análise de Variância , Carcinoma/patologia , Carcinoma de Células Escamosas/patologia , Carcinoma de Células Escamosas/radioterapia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias Nasofaríngeas/patologia , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Prognóstico , Modelos de Riscos Proporcionais , Lesões por Radiação/etiologia , Dosagem Radioterapêutica , Indução de Remissão , Estudos RetrospectivosRESUMO
PURPOSE: Intrauterine tandem placement can be difficult in brachytherapy for cervical cancer. A prospective study was planned to investigate transvaginal ultrasound (TVU) guidance for intrauterine tandem insertions in the treatment of cervix cancer. METHODS AND MATERIALS: Between January 1997 and January 2002, TVU was used after pelvic external beam radiotherapy in 48 cervical cancer patients with a high complication risk because the cervical canal orifice could not be identified and/or the patients could not undergo hysterometry. The TVU findings were graded as 1-4, with a higher number indicating greater difficulty in implantation. The tandem was inserted using the guidance of the TVU findings. Tandem application difficulties were graded in accordance with the number of implantation trials. The relations between tandem applicability and possible factors were analyzed. RESULTS: By TVU, the difficulties in tandem insertion were graded as Grade 1 in 5 cases, Grade 2 in 23 cases, Grade 3 in 17 cases, and Grade 4 in 3 cases. The tandem was inserted in 19 patients on the first try, 12 patients on the second try, 12 patients on the third try, and 2 patients on the fourth try. However, the cervical canal could not be opened in 3 patients. Factors such as median age, stage, chemotherapy, diameter of the tandem applicators, time between external beam radiotherapy and brachytherapy, and the rate of tumor regression were not statistically significant. The ultrasound grade (p = 0.02) and diameter of the tandem applicator (p = 0.007) were statistically significant. Perforation and sepsis were not observed. CONCLUSION: TVU guidance before brachytherapy has a positive contributory effect in reducing the morbidity rate of patients considered high risk.
Assuntos
Braquiterapia/métodos , Ultrassonografia de Intervenção , Neoplasias do Colo do Útero/radioterapia , Adulto , Idoso , Feminino , Humanos , Pessoa de Meia-Idade , Estudos Prospectivos , Dosagem Radioterapêutica , Neoplasias do Colo do Útero/diagnóstico por imagemRESUMO
ABSTRACT Objective: To assess the prognostic factors and results of limb sparing surgery and postoperative radiotherapy (PORT) in patients with non-metastatic soft tissue sarcomas (STS) of the extremities. Methods: Between 1980-2007, 114 extremity-located STS treated with PORT were analyzed retrospectively. Tumors were mostly localized in the lower extremities (71,9%). The median radiotherapy (RT) dose was 60.9 Gy. Chemotherapy was administered to 37.7% of the patients. Tumor sizes were between 3-26 cm (median 7 cm). The three most frequent histological types included undifferentiated pleomorphic sarcoma (26.3%), liposarcoma (25.4%), and synovial sarcoma (13.2%). The median follow-up for all patients was 60 months, and 81 months for survivors. Results: The 5- and 10-year local control (LC) rates were 77% and 70.4%, respectively; actuarial survival rates for 5 and 10 years were 71.8% and 69.1%, respectively. Increasing the dose above 60 Gy for all patients and the patients with positive margins demonstrated a clear benefit on 5-year LC (p=0.03 and p=0.04, respectively). Based on multivariate analysis, the addition of chemotherapy and RT dose were independent prognostic factors for LC. A recurrent presentation significantly affects the disease-free survival. Conclusions: PORT for STS of the extremities provides good long-term disease control with acceptable toxicity in a multidisciplinary approach. Level of evidence III, Retrospective study.
RESUMO Objetivo: Avaliar os fatores prognósticos e os resultados da cirurgia poupadora de membro e radioterapia pós-operatória em pacientes com sarcomas de partes moles das extremidades. Métodos: Entre 1980 e 2007, 114 sarcomas de partes moles localizados em extremidades tratados com cirurgia poupadora de membro e radioterapia pós-operatória foram analisados restrospectivamente. Os tumores localizavam-se principalmente na região mais baixa (71,9%). A dose média da radioterapia foi de 60,9 Gy. A quimioterapia foi usada em 37,7% dos pacientes. Os tamanhos do tumores estiveram entre 3 e 26 cm (mediana de 7 cm). Os três tipos histológicos mais frequentes foram, respectivamente, sarcoma pleomórfico indiferenciado (26,3%), lipossarcoma (25,4%) e sarcoma sinovial (13,2%). O tempo médio de acompanhamento para todos os pacientes foi de 60 meses e 81 meses para sobrevivente. Resultados: As taxas de controle local para 5 e 10 anos foram de 77% e 70,4%, respectivamente, e as taxas de sobrevida foram de 71,8% e 69,1%. Aumentar a dose acima de 60 Gy para todos os pacientes e para aqueles com margens positivas demonstrou claro benefício no controle local de 5 anos (p = 0,03 e p = 0,04, respectivamente). Considerando a análise multivariada, a adição de quimioterapia e a dose de radioterapia foram fatores prognósticos independentes para controle local. Apresentação recorrente afetou significativamente a sobrevida livre da doença. Conclusões: A cirurgia poupadora de membro e radioterapia pós-operatória para sarcomas de partes moles das extremidades fornece bom controle da doença a longo prazo, com toxicidade aceitável na abordagem multidisciplinar. Nível de evidência III, Estudo retrospectivo.
RESUMO
AIMS AND BACKGROUND: To assess the variations in actual doses delivered to the rectum and bladder in the course of postprostatectomy radiotherapy using kilovoltage-cone-beam computed tomography datasets acquired during image-guided radiotherapy. METHODS AND STUDY DESIGN: Twenty consecutive patients treated with intensity-modulated or intensity-modulated arc therapy to the prostate bed were retrospectively evaluated. Both the planning tomography and kilovoltage-cone-beam computed tomography were acquired with an empty rectum and a half-full bladder. Target localization was performed on the basis of soft tissue matching using cone-beam computed tomography scans before each treatment fraction. A total of 16 cone-beam computed tomography scans per patient (acquired at the first 5 fractions and twice weekly thereafter) were used for the assessments. The bladder and rectum were re-contoured offline on each cone-beam computed tomography scan by a single physician, and the delivered doses were recalculated. The variations in certain dose-volume parameters for the rectum and bladder (BD2cc, RD 2cc, V40%, V50%, V60%, V65%) were analyzed using the paired t test. RESULTS: Most of the dose volume variations for rectum and bladder were significantly higher than predicted (P <0.05) for the 320 kilovoltage-cone-beam computed tomography sets, except for the doses received by 2 cc of the bladder and V50 and V60 of the rectum. The dose-volume parameters of the bladder did not meet our criteria of V65 ≤25% and V40 ≤50% in 10% and 20% of the patients, respectively. None of the dose-volume histograms showed rectal V65 ≥17%; however, the rectal V40 ≤35% dose constraint was not met in 11 patients. For all patients, the ANOVA test revealed no significant difference between the variations. CONCLUSION: Actual doses delivered during treatment were found to be higher than predicted, but the majority of calculated bladder and rectal doses remained in the limits of our plan acceptance criteria. Interfraction variability of the rectum and bladder is a major concern in the postprostatectomy radiotherapy setting, even when patients are instructed about rectal and bladder preparation before the radiotherapy course. Image guidance with cone-beam computed tomography at each treatment fraction may offer a viable tool to account for interfraction variations of the rectum and bladder throughout the treatment course.